CCL2-driven inflammation increases mammary gland stromal density and cancer susceptibility in a transgenic mouse model

Xuan Sun¹,², Danielle J. Glynn¹,²,³, Leigh J. Hodson²,³, Cecilia Huo⁴, Kara Britt⁵,⁶, Erik W. Thompson⁴,⁷, Lucy Woolford⁸, Andreas Evdokiou³, Jeffrey W. Pollard⁹, Sarah A. Robertson¹,² and Wendy V. Ingman²,³*

Abstract

Background: Macrophages play diverse roles in mammary gland development and breast cancer. CC-chemokine ligand 2 (CCL2) is an inflammatory cytokine that recruits macrophages to sites of injury. Although CCL2 has been detected in human and mouse mammary epithelium, its role in regulating mammary gland development and cancer risk has not been explored.

Methods: Transgenic mice were generated wherein CCL2 is driven by the mammary epithelial cell-specific mouse mammary tumour virus 206 (MMTV) promoter. Estrous cycles were tracked in adult transgenic and non-transgenic FVB mice, and mammary glands collected at the four different stages of the cycle. Dissected mammary glands were assessed for cyclical morphological changes, proliferation and apoptosis of epithelium, macrophage abundance and collagen deposition, and mRNA encoding matrix remodelling enzymes. Another cohort of control and transgenic mice received carcinogen 7,12-Dimethylbenz(a)anthracene (DMBA) and tumour development was monitored weekly. CCL2 protein was also quantified in paired samples of human breast tissue with high and low mammographic density.

Results: Overexpression of CCL2 in the mammary epithelium resulted in an increased number of macrophages, increased density of stroma and collagen and elevated mRNA encoding matrix remodelling enzymes lysyl oxidase (LOX) and tissue inhibitor of matrix metalloproteinases (TIMP)3 compared to non-transgenic controls. Transgenic mice also exhibited increased susceptibility to development of DMBA-induced mammary tumours. In a paired sample cohort of human breast tissue, abundance of epithelial-cell-associated CCL2 was higher in breast tissue of high mammographic density compared to tissue of low mammographic density.

Conclusions: Constitutive expression of CCL2 by the mouse mammary epithelium induces a state of low level chronic inflammation that increases stromal density and elevates cancer risk. We propose that CCL2-driven inflammation contributes to the increased risk of breast cancer observed in women with high mammographic density.

Keywords: Mammary gland, Development, Macrophage, Chemokine (C-C motif) ligand 2, Mouse model, Mammographic density

* Correspondence: wendy.ingman@adelaide.edu.au

¹The Robinson Research Institute, University of Adelaide, Adelaide, Australia
²Discipline of Surgery, School of Medicine, The Queen Elizabeth Hospital, University of Adelaide, DX465702, 28 Woodville Rd, Woodville 5011, Australia

Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Development and function of the mammary gland is dependent upon dynamic interactions between the mammary gland epithelium and surrounding stroma. Macrophages are a major component of the stroma, and have the capacity to direct a diverse range of biological processes necessary for mammary gland development, including cell proliferation, differentiation, phagocytosis, and tissue remodelling [1–6]. In addition to roles in healthy development, macrophages may also affect cancer susceptibility [7, 8]. Macrophages suppress cancer development as part of innate and adaptive anti-tumour immune responses, through recognition of DNA damaged cells, phagocytosis and antigen presentation to tumour-specific T cells [9–11]. On the other hand, macrophages can promote the proliferation and survival of cancer cells, facilitate tumour cell invasion, increase angiogenesis, and upregulate the production of protumourigenic factors, and thus promote tumour progression [12–14]. In order to exert this wide range of effect in healthy development and cancer susceptibility in the mammary gland, macrophages respond to a variety of different signals in their local microenvironment, including cytokines emanating from other cell types, and components of the extracellular matrix.

CC-chemokine ligand 2 (CCL2), also known as monocyte chemotactic protein 1, is a small pro-inflammatory cytokine and is a highly potent chemoattractant for monocytes and macrophages to sites of tissue injury and inflammation [15, 16]. CCL2 can be highly expressed by both the tumour and surrounding stromal cells in breast carcinomas [17–19]. CCL2 expression in breast carcinomas is highly associated with macrophage infiltration, and its expression is correlated with poor prognosis in breast cancer patients [18–21]. Studies in mice have implicated CCL2 of epithelial tumour cell origin, and macrophages expressing the CCL2 receptor, CCR2, as critical factors in metastasis of breast cancer to the bone and lungs [19, 22]. These studies suggest that epithelial cell-derived CCL2 in carcinomas might promote tumour invasion and metastasis through increased infiltration of macrophages into tumours.

Less understood is the role of CCL2 in healthy breast development and how this may relate to the risk of cancer initiation. CCL2 protein is detected in human breast epithelium [17, 18] and may be responsible for macrophage recruitment under specific conditions. To investigate the effect of CCL2 in mammary gland development and function, we developed a transgenic mouse model Mmtv-Ccl2, whereby CCL2 is constitutively expressed by the mammary epithelium. We found that these mice exhibit increased macrophage recruitment to the mammary gland, perturbed mammary morphogenesis at the proestrus phase of the ovarian cycle and increased abundance of stroma. Overexpression of CCL2 also increased susceptibility to 7,12-Dimethylbenz(a)anthracene (DMBA)-induced mammary tumour development. These key features of the mouse model resemble breast tissue with high mammographic density in women, which is associated with increased stroma and collagen deposition [23, 24], increased immune cell abundance [25], and a fourfold to six-fold increased risk of breast cancer when adjusted for body mass index (BMI) and age [26]. A paired sample analysis of human breast tissue of high and low mammographic density showed that CCL2 protein is higher in tissue with high mammographic density. Combined, these findings suggest that high mammographic density and the associated increased cancer risk may be the result of CCL2-driven inflammation.

Methods
Mice
Animal experiments were approved by the University of Adelaide Animal Ethics Committee and were conducted in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes (7th ed., 2004). All mice were maintained in specific pathogen-free conditions with controlled light (12-h light, 12-h dark cycle) and temperature at the Laboratory Animal Services Medical School facility. Food and water were provided ad libitum. In the experiments we utilised Mmtv-Ccl2 transgenic mice on an FVB background and non-transgenic FVB mice as controls. Estrous cycle stage was determined by analysis of vaginal smears as described previously [27]. Estrous cycles were tracked for at least 28 days.

Generation of Mmtv-Ccl2 transgenic mice
The Mmtv-Ccl2 transgenic mouse, in which the mouse mammary tumour virus 206 promoter (Mmtv) long terminal repeat (generously provided by Dr. William Muller, McGill University) constitutively drives the expression of the chemokine (C-C motif) ligand 2 (Ccl2) mRNA, was generated at the Albert Einstein College of Medicine (New York, USA) by Jiufeng Li. The Mmtv-Ccl2 expression cassette was constructed by insertion of a 3.2-kb EcoRI fragment of the mouse genomic Ccl2 cDNA from the construct pMMJE + 20 [28] into the EcoRI site of the plasmid MMTV-SV40-Bssk, which contain regulatory elements of the Mmtv promoter followed by the SV40 poly A site and the ampicillin-resistance gene (ampr) [29]. DH5-α cells were transformed with this construct by heat shock and selected for ampicillin resistance. DNA was extracted from the successfully transformed cells and the Mmtv-Ccl2 expression cassette was released as a PVUII fragment of 8 kb in size. This purified Mmtv-Ccl2 expression cassette was micro-injected into zygotes of
FVB mice, which were then transferred into pseudo-pregnant recipient mothers.

Twenty-nine offspring were generated, and three founder lines (Mmtv-Ccl2 #13, #20 and #29) were identified by PCR screening using a primer pair (forward: 5'-CGT CCA GAA AAC CAC AGT CA -3'; reverse: 5'-CCG CTC GTC ACT TAT CCT TC-3') covering the Mmtv promoter sequence, which produced a product size of 196 bp (Fig. 1a). All three founders were crossed with background strain FVB mice and the genotypes of all progeny were confirmed by PCR. One female pup was selected from each founder line and the expression of Ccl2 mRNA from different tissues was measured by RT-PCR using a primer pair that spanned both endogenous genomic and exogenous cloned Ccl2 (forward: 5-CCC AAT GAG TAG GCT GGA GA-3'; reverse: 5'-TCT GGA CCC ATT CCT TCT TG-3') and produced product sizes of 451 bp and 125 bp, respectively (Fig. 1a). The offspring from founder 29 exhibited highest expression of mRNA encoding Ccl2 in the mammary gland and was chosen for further analysis. A homozygous Mmtv-Ccl2 transgenic mouse line was successfully established from founder 29 and maintained for over five generations on a FVB background.

DMBA-induced tumour susceptibility

Susceptibility of mice to mammary gland tumours was investigated using the DMBA-induced mammary tumour model. This model is superior for this purpose over other mouse mammary tumour models, such as transgenic expression of polyoma middle T oncogene targeted to the mammary mouse mammary gland, because tumour development does not occur with 100% penetrance, enabling quantification and statistical analysis of cancer susceptibility. Mmtv-Ccl2 and FVB mice received DMBA in sesame oil (1 mg/ml) weekly by oral gavage for 6 weeks from 6 weeks of age. General health and signs of tumour development were monitored weekly. To detect tumours, the mammary glands were gently palpated. Mice were killed when tumours were detected and the tumours dissected, formalin-fixed and paraffin-embedded.

Tissue morphology and histology

To analyse the morphology of the mammary gland, mammary glands were dissected from mice and spread on a glass slide. The mammary gland whole mounts were incubated in Carnoy’s fixative and stained in carmine alum as described previously [30]. To analyse mammary gland histology, mammary glands were dissected from mice and fixed in 4% paraformaldehyde (PFA) (Sigma-Aldrich) for 24 h at 4 °C. Paraffin-embedded tissue was cut on a Leica Rotary Microtome (Leica Microsystems) and placed onto SuperFrost Plus slides. Slides were dried overnight at 37 °C. Blocks and sections were stored at room temperature prior to staining.

Haemotoxylin and eosin staining was performed on paraffin-embedded sections. The sections were dewaxed.
in Safsolv (Ajax, Finechem, Australia) and passed sequentially through 100%, 95%, 80% and 70% ethanol for rehydration. The sections were stained with haematoxylin and counterstained with eosin and then mounted on coverslips.

Masson’s Trichrome stain was used for detection of collagen fibres in paraffin-embedded mouse mammary gland tissue (all reagents were from Sigma-Aldrich). Slides were placed in Bouin’s fluid overnight at room temperature. The following day, slides were placed in Weigert’s Haematoxylin working solution (50% A and 50% B) for 10 minutes at room temperature and immersed in 80% ethanol before washing with MQ water. Slides were placed in Biebrich Scarlet solution for 2 minutes and immersed in 5% phosphotungstic acid for 15 minutes followed by immersing in Light green solution for 10 minutes. Slides were immersed in 1% glacial acetic acid for 5 minutes prior to dehydration, clearing and mounting.

**Immunohistochemistry**

Proliferating cells were identified by bromodeoxyuridine (BrdU) immunostaining of paraffin-embedded mammary gland tissue. One hour prior to sacrifice, mice received an intraperitoneal (i.p.) injection of 100 μl of 10 mg/ml BrdU (Sigma). Sections were stained for BrdU incorporation into DNA using a BrdU In-Situ Detection Kit (BD Biosciences Pharmingen) according to the manufacturer’s instructions.

Apoptotic cells were identified by terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) staining of paraffin-embedded mammary gland tissue. Sections were stained with the In-Situ Cell Death Detection Kit (Roche) according to the manufacturer’s instructions. Only BrdU and TUNEL positive cells clearly located within the ductal or alveolar epithelium were included in the analysis.

Macrophage abundance was determined by F4/80 antibody staining. Five micrometer paraffin-embedded sections mounted on glass slides were incubated with rat anti-F4/80 monoclonal antibody (1:100 dilution; overnight at 4 °C) (Caltag Laboratories, Burlingame, CA, USA) followed by biotinylated rabbit anti-rat IgG (1:200 dilution; 40 minutes at room temperature) (Vector Laboratories) and ABC Elite kit (Vector Laboratories) with 3,3’ diaminobenzidine (DAB) peroxidase (DAKO, Denmark).

CCL2 was detected with polyclonal rabbit anti-mouse CCL2 (Santa Cruz Biotechnology, CA, USA) in 5-μm paraffin-embedded sections mounted on glass slides. For antigen retrieval, slides were placed in 10 mM sodium citrate buffer (pH 6) and brought to 90 °C in a water bath for 20 minutes and washed two times in PBS for 3 minutes each. Following CCL2 antibody incubation (1:50 dilution; overnight at 4 °C), sections were incubated with goat anti-rabbit HRP (1:200 dilution; Dako) for 60 minutes at room temperature. The detection of bound antibody was performed using DAB according to the manufacturer’s instructions.

Collagen-1 was detected using Alexa Fluor® 594 goat-anti rabbit IgG (Chemicon, MA, USA, 1:800 dilution). Slides stained with secondary antibodies only or with isotype-matched antibody were included as negative controls. All sections were mounted in fluorescent mounting medium (Dako, Glostrup, Denmark) with 4’6-diamidino-2-phenyindol (DAPI) (Sigma, St Louis, USA) and were stored at 4 °C in the dark until image capture.

**Histology, pathology and immunohistochemistry quantification**

Fluorescence images of collagen-1 and TUNEL-positive apoptotic epithelial cells were captured and collected using FV10i Confocal Microscope (Olympus, USA) with laser-power and photomultiplier settings kept constant for all experiments, and images were captured at ×60 magnification. Non-fluorescent stained tissue sections were captured as a digital image using a Nanoszoomer 1.0 (Hamamatsu, Shizouka, Japan) at a zoom equivalent to a ×40 objective lens. Whole mount images of mammary glands were captured by MZ16 FA-Stereo microscope (Leica, The University of Adelaide, SA, Australia).

An assessor blinded to mouse genotype performed all quantification analysis. To determine the extent of ductal branching morphogenesis in whole-mounted mammary glands, the three longest ducts from each mammary gland were selected, the number of branch points on each duct was counted manually, and a mean value of three ducts per mammary gland were calculated and expressed as branch points/mm.

To quantify the extent of alveolar development in H&E-stained sections, epithelium was categorized as ductal (single epithelium layer) or alveolar (clusters of epithelial structures containing alveolar lumens) and the numbers of ductal and alveolar epithelial structures were counted manually as described previously [31, 32]. The total number of alveolar buds was expressed as percentage of total epithelial structures (ductal plus alveolar).

To determine the ratio of stroma and epithelium area within the mammary gland in H&E-stained sections, five ductal epithelium and alveolar epithelium regions were randomly chosen for quantification. The area of stroma and epithelium was measured and represented as stroma area (mm²)/epithelium area (mm²). To determine the number of epithelial cells within the ductal epithelium, the number of haematoxylin-positive nuclei was counted.

To determine the deposition of collagen around mammary epithelium, the amount of fibre stain (green) around five randomly chosen ductal epithelia and alveolar epithelia was quantified. To determine the number of
proliferating epithelial cells and apoptotic epithelial cells, the number of BrdU-positive cells and TUNEL-positive cells within the epithelium was counted respectively. The number of F4/80-positive cells in the mammary gland was counted and only positive cells with visible haematoxylin-stained nuclei were included. For F4/80 staining, F4/80-positive macrophages were distinguished from F4/80-stained eosinophils on the basis of nuclear morphology. All results were expressed as positive cells/mm² or percentage of positive cells. The mean density of positive cells within the five ductal and the five alveolar stroma regions was calculated, and grouped by mouse genotype.

The thickness of total collagen (indicated by red arrows) around each selected ductal epithelium was measured, quantified and represented as collagen thickness/μm (E). The intensity of collagen I was also measured around each selected ductal epithelium, and was quantified and represented as collagen I density (arbitrary unit) (F). The mean fluorescence intensity (mean grey-scale value) of collagen I was determined and analysed using ImageJ software and a mean value of five randomly chosen epithelial ducts was calculated.

Haemotoxylin and eosin stained sections of DMBA-induced mammary tumours were assessed by a veterinary pathologist (LW). The tumours were classified and scored for mitotic index and inflammation grade. Mitotic index was determined by counting the number of mitotic cells in a 10× field of view. Inflammation was scored on a scale of 0–5, which took into account degree of inflammation and degree of dispersion as either 0 (none), 1 (mild, focal), 2 (mild, multifocal), 3 (moderate, focal), 4 (moderate, multifocal) or 5 (marked, diffuse or multifocal).

CCL2 ELISA
All tissues and serum were collected under sterile conditions, and the tissue was snap frozen in liquid nitrogen and stored at −80 °C until processing. Protein was extracted from tissues in RIPA buffer containing Complete Protease Inhibitor Cocktail Tablets (Roche, Basel, Switzerland). Protein concentration of each sample was quantified using the BCA protein assay (Thermo Scientific) following the manufacturer’s instructions. The limit of detection was between 20 μg/ml and 2000 μg/ml.

A CCL2-specific sandwich ELISA (eBioscience, San Diego, CA, USA) was used to quantify mouse CCL2 protein in different tissues, according to the manufacturer’s instructions. Briefly, an anti-mouse CCL2 antibody was coated onto a 96-well microtitre plate to capture CCL2 from either recombiant standard or assay samples. A biotinylated anti-mouse CCL2 detection antibody was then used and bound antibody was quantified by the addition of streptavidin-conjugated horseradish peroxidase (HRP), followed by the addition of a chromagen substrate. After incubation for 20 minutes at room temperature, the substrate product was acidified by the addition of 50 μl of 1 M HCl, and absorbance at 450 nm (reference wavelength 570 nm) was measured using a Benchmark™ microplate reader (Bio-Rad Laboratories). The concentration of CCL2 within tissues and serum was then calculated from a standard curve (five-parameter logistic curve) using known concentrations of recombinant CCL2. This assay was reported by the manufacturer to have a minimum detection limit of 15 pg/ml, with intra-assay and inter-assay precision of approximately 5%. The concentration of CCL2 in each sample is expressed relative to the protein concentration of the tissue, e.g. CCL2 (pg)/protein (pg).

mRNA expression
Spleen, mammary gland, kidney, ovary and salivary gland were dissected from Mmtv-Ccl2 and FVB mice to quantify expression of Ccl2, Mmtv, Mmp2, Mmp9, Lox, Timp1, Timp2 and Timp3 mRNA expression. Total RNA was extracted using Trizol (Invitrogen) and treated with DNase (DNA free; Ambion), then first-strand cDNA was reverse transcribed from 3 μg random hexamer-primed RNA employing a Superscript-III Reverse Transcriptase kit. Primer pairs specific for published cDNA sequences were designed using Primer Express version 2 Software (Applied Biosystems, Foster City, CA, USA). The following primer pairs were used to detect specific cDNAs: Actb 5’ GTC TGT TCA GCG CAT TATT C; Mmp2 5’ CCA GCA ATG TCA ACA GAT GT 3’ GAG CCT GAA CCA CAG GTA CCA GCA AGG AGC AAT GAT CTT GAT; Ccl2 5’ CCA GCA AGA TGA 3’ CCA TCA GTC ACT TAT CCT CT; Mmp9 5’ CAA GAC ACG TGG TGC CAT GCC A 3’ TGT CTC GCG GCA AGT CTG C; Timp2 5’ GAG CCT GAA CCA CAG GTA CCA 3’ GTC CAT CCA GAG GCA CTC ATC; Timp3 5’ CTT CTG CAA TCT CAG CAG GAA GAC AAC GA; Mmtv 5’ CGT CCA GAA AAC CAC AGT CA 3’ CGG CTC GTG ACC TAT TAT C; Lox 5’ TGC CAG TGG TAT GAT ATT ACA GAT GT 3’ AGC GAA TGT CAT CAC AGG GAA CAA.

PCR amplification was performed in duplicate in an ABI Prism 7000 Sequence Detection System (Applied Biosystems) using SYBR Green PCR Master Mix (Applied Biosystems). Reaction products were analysed by dissociation curve profile and by 2% agarose gel (wt/vol) electrophoresis. Assay optimization and validation experiments were performed to define the amplification efficiency of each primer pair as described previously [33]. Messenger RNA abundance values were normalized independently to Actb mRNA expression, and data are plotted as relative expression in arbitrary units, adjusted such that the mean of the wild-type control group is assigned a value of 1.
Quantification of CCL2 in paired human breast tissue samples

To investigate the relationship between mammographic density and CCL2, immunohistochemistry to detect CCL2 was conducted on paired breast tissue samples of high mammographic density (HMD) and low mammographic density (LMD). This approach has been described previously [23, 25], and offers excellent scope to study histological parameters associated with HMD in small sample sizes, as paired-sample statistical analysis can be applied.

Briefly, ethics approval from the Peter MacCallum Human Research Ethics Committee (number 08/21) and St. Vincent’s Hospital, Victoria was obtained and the study conducted in accordance with the Australian National Statement on Ethical Conduct in Human Research. Breast tissue was collected from women undergoing prophylactic mastectomy for breast cancer prevention consented to the study through the Victorian Cancer Biobank (VCB 10010). These women had a confirmed BRCA1/2 carrier status, a past history of breast cancer in the other breast or a family history of two or more first-degree or second-degree relatives with breast cancer who were diagnosed before the age of 50 years. Resected breast tissue was transferred immediately on ice to the pathology department upon completion of mastectomy, where pathologists resected slices of breast tissue using a sterile technique. X-rays of those slices were taken by a breast radiographer using uniform radiological parameters and were assessed against a calibration ruler for selection of HMD and LMD regions. The tissue slice was transferred to a biosafety level-2 hood, where areas that appeared white on X-rays were selected and removed using sterile blades and defined as HMD regions, and areas that appeared black were similarly selected, removed and classified as LMD regions. The HMD and LMD regions were subjected to routine formalin fixation and paraffin embedding.

Paraffin-embedded human breast tissue sections were placed on a hotplate at 60 °C for 60 minutes before dewaxing in two 5-minute washes in Safsolv and gradually passed through 100%, 95%, 80% and 70% ethanol for rehydration as described previously [23, 25]. Before sections were incubated with mouse anti-human CCL2 antibody (R&D systems) for 30 minutes at room temperature, sections were placed in Dako EnVision™ low pH antigen retrieval solution (Dako) and brought to 90 °C in a water bath for 20 minutes followed by Envision™ wash buffer and endogenous peroxidase block. After primary antibody incubation, sections were incubated with Dako EnVision™ HRP (ready-to-use, Dako) for 30 minutes at room temperature and washed in Envision™ wash buffer for 5 minutes. The detection of bound antibody was performed according to the manufacturer’s instructions. Tissue sections were counterstained with haematoxylin prior to dehydration, and cleared and mounted as described above. Slides stained with isotype-matched primary antibody were included as negative controls.

Stained tissue sections were captured as a digital image using a Nanozoower 1.0 (Hamamatsu, Shizouka, Japan) at a zoom equivalent to a × 40 objective lens. All quantification analysis was performed blinded. Three epithelium clusters were randomly selected from each section for quantification. To determine the intensity of CCL2-positive staining within the epithelium of each cluster, staining was quantified using the IHC profiler within Image J analysis software. The percentage of positive staining was determined by combining percentage of high, medium and low positive staining within each selected epithelium measured by the IHC profiler and the mean value of three clusters per patient was calculated.

Statistical analysis

Data were assessed for normal distribution with a Shapiro-Wilk normality test using GraphPad Prism 5 (GraphPad software Inc, San Diego, CA, USA) or SPSS Statistics Version 17.0 (IBM Corporation, Armonk, NY, USA). Normally distributed data were analysed using the unpaired t test with the exception of paired high and low mammographic density samples, which were analysed by paired t test. Not normally distributed data were analysed using the Mann–Whitney U test. Data are presented as the mean ± SEM (standard error of mean). Kaplan–Meier survival curves were generated using SPSS Statistics Version 17.0 to analyse survival function and the log rank test was used to compare different Kaplan–Meier curves between groups. Tumour incidence was analysed by the chi-squared test. The difference between control and transgenic groups was considered statistically significant if p < 0.05 and is indicated on the figures by an asterisk.

Results

Elevated expression of Ccl2 mRNA and protein in Mmtv-Ccl2 mice

To determine whether CCL2 abundance was elevated in transgenic mice, mRNA encoding the MMTV promoter and CCL2, and CCL2 protein, were investigated in offspring from mouse founder line #29. CCL2 protein was clearly detectable in the lumen of the mammary gland of Mmtv-Ccl2 mice by immunohistochemistry, and was substantially elevated compared to the very low abundance in non-transgenic control mice (Fig. 1b and c). No positive staining was observed in the mammary epithelium stained with isotype-matched negative control antibody (not shown). Messenger RNA encoding MMTV
was virtually undetectable in the spleens, kidneys, ovaries and livers of all mice, and in the mammary gland and salivary gland of non-transgenic control mice (Fig. 1d). However, abundance of mRNA encoding MMTV was detectable in the mammary gland and salivary gland of Mmtv-Ccl2 mice and was 15-fold and 125-fold higher, respectively, compared to control mice.

Consistent with previous studies using CCL2 expression cassettes driven by different promoters [34, 35], elevated abundance of CCL2 was observed not only in the tissue of interest, but also in other tissues and in the blood of Mmtv-Ccl2 mice. Abundance of Ccl2 mRNA was significantly elevated in the spleen, kidney, salivary gland, mammary gland and liver of Mmtv-Ccl2 mice compared to control mice (Fig. 1e). The abundance of CCL2 protein was also elevated in the spleen, liver, salivary gland, and mammary gland and in the serum of Mmtv-Ccl2 mice compared to control mice (Fig. 1f).

### CCL2 overexpression increases recruitment of macrophages to the mammary gland

F4/80 immunohistochemistry was performed to investigate the effect of epithelial cell-derived CCL2 on the number of macrophages in the mammary gland. F4/80-positive macrophages were observed in close proximity to ductal and alveolar epithelium in the mammary glands from both control (Fig. 2a and c, respectively) and Mmtv-Ccl2 mice (Fig. 2b and d, respectively). No positive staining was observed in the mammary glands stained with isotype-matched irrelevant antibody (not shown). The density of macrophages in regions surrounding both ductal and alveolar epithelium was increased in Mmtv-Ccl2 mice compared with control (Fig. 2e).

### CCL2 overexpression perturbs mammary gland morphogenesis during the estrous cycle

CCL2 overexpression did not affect estrous cyclicity. Estrous cycle length was (mean ± SEM) 5.4 ± 0.1 days for both Mmtv-Ccl2 and control mice (n = 29 per genotype). There was no significant difference between the two groups in the percentage of time spent in each of the four stages of the estrous cycle. To assess the impact of CCL2 overexpression on mammary gland development across the estrous cycle, adult mammary glands from control and Mmtv-Ccl2 transgenic mice were dissected at the different stages of the cycle and compared morphologically and histologically (Fig. 3). Despite normal secondary branching and alveolar architecture during the development phase of the cycle (metestrus and diestrus) in transgenic mice, Mmtv-Ccl2 mice exhibited increased density of branch points (Fig. 3k) and an increase in the tissue area comprised by alveolar epithelium (Fig. 3l) at the proestrus phase of the cycle, suggesting a perturbation in the cyclic regression of the mammary gland. Thus, mammary gland function at the proestrus phase of the cycle was investigated in further experiments.

To investigate the effect of CCL2 on epithelial cell turnover at the proestrus phase of the cycle, mammary glands from Mmtv-Ccl2 and control mice were stained for BrdU, indicative of cell proliferation, and TUNEL, indicative of cell death. BrdU-positive cells were observed in both ductal and alveolar epithelium of mammary glands from control (Fig. 4a and c, respectively) and Mmtv-Ccl2 (Fig. 4b and d, respectively) mice. There was no significant difference in the density of proliferating ductal or alveolar epithelial cells in Mmtv-Ccl2 compared to control mice (Fig. 4i). TUNEL-positive cells were observed in both ductal and alveolar epithelium of...
mammary glands from control (Fig. 4e and g, respectively) and Mmtv-Ccl2 (Fig. 4f and h, respectively) mice. There was no significant difference in the density of TUNEL-positive ductal or alveolar epithelial cells in Mmtv-Ccl2 compared to control mice (Fig. 4j).

Upon further examination of H&E-stained thin sections, an increased thickness of stroma surrounding epithelial ducts was evident in the mammary glands of transgenic mice. To investigate this, the ratio of stroma to epithelium was quantified in H&E-stained sections from control and Mmtv-Ccl2 mice at proestrus (Fig. 5a and b, respectively). There was a twofold increase in the area of stroma relative to epithelium in Mmtv-Ccl2 mice (Fig. 5c). The increase in stroma in CCL2-overexpressing mice was further investigated by analysing the extracellular matrix. The thickness of collagen, assessed by Masson’s trichrome stain, in control and Mmtv-Ccl2 (Fig. 5d and e, respectively) mice was increased (Fig. 5f) however the abundance of monomeric collagen I detected by collagen I antibody staining was comparable in Mmtv-Ccl2 mice (Fig. 5g-i).

Quantitative RT-PCR was used to analyse the expression of mRNA encoding enzymes that are involved in collagen remodelling. The abundance of both lysyl oxidase (Lox) and tissue inhibitor of metalloproteinase 3 (Timp3) mRNA were increased in mammary glands of Mmtv-Ccl2 mice compared to control mice, while matrix metalloproteinase 2 (Mmp2), Mmp9, Timp1 and Timp2 mRNA were not significantly altered (Fig. 5j). Combined, these results suggest that CCL2 overexpression causes increased abundance of stroma surrounding epithelium through perturbation of remodelling of the extracellular matrix.

CCL2 overexpression increases susceptibility to DMBA-induced mammary gland cancer

To investigate the effect of CCL2 overexpression on mammary gland cancer susceptibility, control and Mmtv-Ccl2 mice were challenged with the chemical carcinogen DMBA. Tumour free survival was analysed on a Kaplan–Meier plot (Fig. 6). The incidence of mammary tumours was higher in Mmtv-Ccl2 mice, with 14 of 18 mice (78%) developing a mammary gland tumour compared to 8 of 18 (44%) control mice developing a mammary gland tumour (p = 0.04). There was also a significant decrease in mammary tumour-free survival in Mmtv-Ccl2 mice compared to control mice (p = 0.025);
Mean latency (mean ± SD) was 12.7 ± 1.0 weeks in Mmtv-Ccl2 mice, and 16.7 ± 1.4 weeks in control mice. Analysis of a subset of the tumours revealed the majority represented adenosquamous carcinomas, with early mammary intraepithelial neoplasia and other carcinoma types present (Table 1). The mitotic index and inflammation score varied widely between tumours, and there was no significant difference in these parameters between control and Mmtv-Ccl2 mice.

Epithelial cell CCL2 is increased in breast tissue of high mammographic density in women

The increase in stroma, collagen and mammary cancer risk in Mmtv-Ccl2 mice resembled key clinical and histological features of HMD in women. To investigate whether epithelial cell-derived CCL2 might be associated with HMD, CCL2 was quantified in paired breast tissue samples biopsied from regions of high and low density from women undergoing prophylactic mastectomy.
CCL2 staining was observed in the epithelium of human breast tissue of low and high mammographic density, while no staining was present in isotype-matched antibody control sections (Fig. 7). A few cells within the stromal compartment also stained positive for CCL2; however, the abundance of these scarce cells did not appear to be affected by density. Abundance of CCL2 in epithelial cells, as measured by intensity of CCL2 staining, was increased in tissue with HMD compared to the paired LMD tissue from the sample patient ($p = 0.03$).

**Discussion**

This study investigated the significance of CCL2 in regulating macrophage recruitment, healthy mammary gland development, and the risk of cancer. Overexpression of CCL2 by the mammary gland epithelium was achieved through generation of a transgenic mouse model wherein Ccl2 mRNA expression was under the control of the mammary epithelial cell-specific promoter MMTV. Consistent with the known role of CCL2 as a macrophage chemoattractant [36, 37], constitutive expression of epithelial cell-specific CCL2 resulted in increased abundance of stromal macrophages in the mammary gland. Therefore, this mouse model enabled the examination of the effect of CCL2 on macrophage infiltration, collagen remodelling, cyclic mammary gland regression and DMBA-induced cancer risk.

**CCL2 overexpression perturbs mammary gland regression and collagen remodelling**

In cycling non-pregnant mice, the mammary epithelium undergoes ductal development and regression over the course of each ovarian cycle under the influence of ovarian hormones [31]. For the mammary gland to undergo...
these dynamic developmental processes, tight regulation of signals within the cytokine microenvironment that affect the balance between proliferation, differentiation, and apoptosis, and tissue breakdown and repair is required [8, 38]. Increased ductal branch points and abundance of alveolar buds observed in mice overexpressing CCL2 at the proestrus phase of the cycle suggests that despite normal estrous cyclicity, mammary gland regression was perturbed. However, at estrus, the mammary epithelium exhibited a normal basic ductal structure, implying that regression is delayed rather than completely inhibited.

Little is known of the role of CCL2 in mammary gland development and function; however, some studies suggest that it may be involved in mediating inflammation associated with the early response to tissue injury and post-weaning involution. Elevated expression of CCL2 is observed during the first stage of mammary gland involution, where it is believed to be involved in early recruitment of macrophages, and decreases during the later stage of involution when tissue remodelling peaks [39]. Lipopolysaccharide administered to the lactating mammary gland increases abundance of CCL2, which precedes macrophage recruitment and partial mammary gland involution [40]. These instances of acute elevation in CCL2 may form part of the immune signalling fingerprint that promotes an inflammatory response; however, later suppression of CCL2 may be required for appropriate tissue remodelling.

![Fig. 6](image)

**Fig. 6** The effect of CCL2 overexpression on mammary gland cancer susceptibility in mice. Kaplan-Meier survival plot showing the percentage of tumour-free mice following 7,12-Dimethylbenz(a)anthracene (DMBA) treatment in weeks for control and Mmtv-Ccl2 mice; n = 18 per group. In Mmtv-Ccl2 mice, the incidence of mammary tumours was increased (p = 0.04 chi squared) and mammary tumour-free survival was reduced (p = 0.025 log rank) compared to control mice.

### Table 1 Characteristics of DMBA-induced tumours from control and Mmtv-Ccl2 mice

| Genotype   | Latency (weeks) | Histopathology            | Mitotic index | Inflammation |
|------------|-----------------|----------------------------|---------------|--------------|
| Control    | 13              | Spindeloid carcinoma       | 0             | 2            |
|            | 10              | Adenosquamous carcinoma    | 3             | 5            |
|            | 14              | Adenosquamous carcinoma    | 2             | 2            |
|            | 16              | Early MIN                  | 0             | 0            |
|            | 10              | Adenosquamous carcinoma    | N/A           | 4            |
|            | 12              | Adenosquamous carcinoma    | 1             | 4            |
|            | 11              | Carcinosarcoma             | 0             | 2            |
|            | 10              | Early MIN                  | 0             | 1            |
| Mmtv-Ccl2  | 10              | Acinar                     | 0             | 0            |
|            | 11              | Adenosquamous carcinoma    | N/A           | 2            |
|            | 10              | Adenosquamous carcinoma    | 2             | 5            |
|            | 19              | Early MIN                  | 0             | 0            |
|            | 10              | Adenosquamous carcinoma    | 0             | 2            |
|            | 13              | Glandular carcinoma        | 0             | 2            |
|            | 13              | Cribriform carcinoma       | 1             | 4            |
|            | 8               | Adenosquamous carcinoma    | 1             | 5            |
|            | 19              | Early MIN                  | 0             | 0            |

Latency in weeks after final 7,12-Dimethylbenz(a)anthracene (DMBA) administration. Mitotic index was determined by counting the number of mitotic cells in a × 10 field of view. Inflammation was scored as 0 (none), 1 (mild, focal), 2 (mild, multifocal), 3 (moderate, focal), 4 (moderate, multifocal) or 5 (marked, diffuse or multifocal). MIN mammary intraepithelial neoplasia, N/A not assessed.
Mammary gland regression during the ovarian cycle involves a series of processes, including apoptosis of the mammary epithelial cells, clearance of dying epithelial cells by phagocytosis and remodelling of mammary extracellular matrix [7, 41]. Epithelial cell proliferation and apoptosis was unaffected by constitutive expression of the Ccl2 transgene by mammary epithelium, which suggests that CCL2 might not affect epithelial cell turnover in the adult cycling mammary gland. However, the stromal area around ductal mammary epithelium was significantly larger in the presence of epithelial cell-derived CCL2, and therefore CCL2 might be involved in regulation of the process of stroma breakdown and repair necessary for cyclic remodelling.

Mammary gland stroma is composed of extracellular matrix proteins, and a wide variety of cells, including fibroblasts and leukocytes such as macrophages and eosinophils. Collagen is a prominent component of extracellular matrix in the mammary gland stroma that contributes significantly in supporting tissue integrity and elasticity; furthermore; the deposition and remodelling of collagen has been found to be highly associated with normal mammary gland development and tumourigenesis [42–44]. Increased Timp3 mRNA expression was observed in CCL2 overexpressing mice, indicating CCL2 may enhance the inhibitory effect of TIMPs on MMP-mediated collagen degradation, resulting in elevated collagen deposition. Moreover, high expression of epithelial cell-derived CCL2 also causes increased expression of lysyl oxidase mRNA (Lox), a collagen crosslinking enzyme involved in crosslinking elastin and collagen in extracellular matrix and hence, enhancing tissue integrity [44]. This could also contribute to the increased collagen deposition around mammary epithelium in the presence of abundant CCL2, as increased LOX expression could lead to increased mammary gland stromal stiffness and collagen crosslinking, which could further inhibit MMP-mediated collagen degradation. Although mRNA for collagens and other collagen biosynthesis proteins were not assessed, their coordinated upregulation is feasible.

CCL2-driven inflammation is known to promote fibrosis and collagen deposition in a number of disease states, including human pulmonary fibrosis [45], bleomycin-induced pulmonary fibrosis in rats and mice [46, 47], and interstitial renal fibrosis in mice [48]. Macrophages are an essential mediator of inflammation-associated fibrosis, and have been shown to promote collagen synthesis in vitro [49–51]. In the mammary gland, macrophages promote collagen fibrillogenesis as a critical part of healthy pubertal development [2]. Therefore, increased abundance of mammary gland macrophages, stroma and collagen in CCL2 overexpressing mice is consistent with the known role of CCL2 in driving inflammation and collagen deposition.

These findings suggest that CCL2-driven inflammation increases collagen deposition and inhibits collagen remodelling around the mammary epithelium. Through
promotion of macrophage recruitment and the activities of TIMP3 and LOX, high CCL2 expression would be expected to cause imbalance in the turnover of collagen, which in turn could impair mammary gland regression during the prooestrus phase of the ovarian cycle.

**CCL2-driven breast cancer risk**

It is well-established that chronic inflammation increases cancer risk through oncogenic mutations, genome instability, early tumour promotion, and enhanced angiogenesis [13, 14]. Chronic inflammation leads to collagen deposition and fibrosis associated with increased LOX expression [52] and increased stromal collagen deposition has also long been recognised as a major contributing factor to the increased mammographic density that increases risk of breast cancer [23, 25, 53, 54]. This study suggests that expression of epithelial cell-specific CCL2 by mammary epithelium increases mammary cancer susceptibility in mice through inducing a low level of chronic inflammation in the mammary gland, characterised by increased macrophage infiltration and fibrosis associated with perturbed collagen deposition and remodelling. However, further studies to dissect the contribution of macrophages to this phenotype are required to establish their role in the increased mammary cancer risk observed in Mmtv-Ccl2 transgenic mice.

Population studies support the notion that increased CCL2 expression increases breast cancer risk and cancer progression. The risk of developing metastasis is significantly increased in patients with breast cancer who carry the CCL2-2518 A/G promoter polymorphism, compared to A/A homozygotes [55]. The A/G genotype causes increased CCL2 production in monocytes after stimulation compared to the A/A genotype [56] and may similarly affect CCL2 expression by mammary epithelium. However, it is unknown whether the protein concentration of CCL2 in the transgenic mice is similar or above the physiological concentration of CCL2 that might be present in the human breast. In addition, altered responsiveness to CCL2 through polymorphism in the receptor CCR2 also affects breast cancer susceptibility. The CCR2-64I polymorphism, which slightly impairs capacity to transduce CCL2 signals, is underrepresented in patients with breast cancer [17, 57], and this might provide protection from tumour formation through reduced recruitment of tumour-promoting macrophages.

High mammographic density is associated with fourfold to six-fold increased breast cancer risk in the highest versus lowest quartiles, and the association remains after correction for BMI and age [26]. Although the biological mechanisms that regulate mammographic density are poorly understood, HMD is associated with increased stroma, collagen deposition and TIMP3 protein compared to tissue of LMD [58–60]. These biological characteristics are strikingly similar to the mammary glands of Mmtv-Ccl2 transgenic mice, in which overexpression of CCL2 caused increased abundance of stroma, collagen thickness, mRNA encoding TIMP3 and elevated risk of DMBA-induced mammary cancer. An inflammatory basis for HMD is suggested by studies in paired samples of high and low mammographic density tissue. Tissue with HMD exhibits elevated inflammatory COX2, increased number of vimentin-positive immune cells within the epithelium, and reduced abundance of CD206-positive “alternatively activated” macrophages compared to paired breast tissue samples of LMD [25, 61, 62], and the increase in CCL2 reported here. Based on these observations, we propose that CCL2-driven inflammation might play a role in increasing mammographic density and breast cancer risk.

The potential role of inflammation in driving high mammographic density suggests that use of non-steroidal anti-inflammatory drugs (NSAID), which are already known to reduce breast cancer risk [63, 64], could be effective in reducing mammographic density. In a mouse model of HMD, Celecoxib, a selective NSAID that specifically inhibits COX2, was shown to reduce collagen deposition in the mammary gland, and reduce tumour development and metastasis [65]. Although there appears to be no association between NSAID use and mammographic density [66], a study of nearly 30,000 postmenopausal women found that NSAID use reduced the risk of increasing mammographic density over a period of 9–28 months [67]. Further studies investigating the potential for NSAID to reduce breast cancer risk associated with HMD are required.

**Conclusion**

Constitutive expression of CCL2 by the mouse mammary epithelium induces a state of low level chronic inflammation that perturbs collagen remodelling and elevates cancer risk. We propose that CCL2-driven inflammation contributes to the increased risk of breast cancer observed in women with HMD. Future studies will examine how CCL2 is regulated in the mammary gland, and the biological function of CCL2 in increasing mammographic density in women. Understanding the underlying cellular mechanisms of how inflammation affects breast function will shed light on cancer susceptibility and may uncover new opportunities to therapeutically reduce breast cancer risk.

**Abbreviations**

Ampr: ampicillin-resistance gene; BMI: body mass index; bp: base pairs; BrdU: bromodeoxyuridine; CCL2: CC-chemokine ligand 2; CCR2: CCL2 receptor; DAB: 3,3-diaminobenzadine; DAPI: 4',6-diamidino-2-phenylindol; DMBA: 7,12-Dimethylbenz[a]anthracene; ELISA: enzyme-linked immunosorbent assay; HMD: high mammographic density; LMD: low mammographic density; LOX: lysyl oxidase; MNP: matrix metalloproteinase; MMTV: mouse mammary tumour virus 206 promoter; NSAID: non-steroidal anti-inflammatory drugs; PFA: paraformaldehyde; SEM: standard error of the mean; TIMP: tissue inhibitor of matrix metalloproteinases; TUNEL: terminal deoxynucleotidyl transferase dUTP nick end labelling.
Acknowledgements
We thank Jiufeng Li for the preparation of the transgenic construct.

Funding
This work was supported by the Australian National Breast Cancer Foundation (NBCF), the Hospital Research Foundation (HRF), the Victorian Breast Cancer Research Consortium, the St. Vincent’s Hospital Research Endowment Fund, and the University of Melbourne Research Grant Support Scheme, the Wellcome Trust 101067/Z/13/Z (JWP), Medical Research Council Centre for Reproductive Health grant G1002033 (JWP) and NIH grants ROI CA172451 (JWP). XS was supported by University of Adelaide Graduate Research Scholarship and Florey Medical Research Foundation Postgraduate Cancer Research Top Up Scholarship. C.W.H was supported by the Australian Postgraduate Awards scholarship. KB is supported by an NBCF Early Career Fellowship. D.W.F. was supported in part by the NBCF. A.E. is a THRF Fellow. W.V.I. is an NBCF/THRF Fellow.

Availability of data and materials
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
Transgenic mouse studies, tissue histology and quantification were conducted by XS, D.J.G, L.J.H. and W.V.I. Paired breast tissue biopsies were collected and prepared by CH, KB and ET, and stained for CCL2 by XS. Histopathological analysis was conducted by LW. Conception and design of the study was conducted by XS, WWI, SAR, JWP, SAR and AE. Analysis and interpretation of data was conducted by XS, WWI, ET, KB, JWP, SAR and AE. The draft of the manuscript was written by XS, with all authors providing critical intellectual input into the final manuscript. All authors have read and approved the final version of the manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethical approval and consent to participate
Animal experiments were approved by the University of Adelaide Animal Ethics Committee and were conducted in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes (7th ed., 2004). Human ethics approval from the Peter MacCallum Human Research Ethics Committee (number 08/21) and St. Vincent’s Hospital, Victoria was obtained and the study was conducted in accordance with the Australian National Statement on Ethical Conduct in Human Research. Women consented to the study through the Victorian Cancer Biobank (VCB 10010).

Author details
1Discipline of Obstetrics and Gynaecology, School of Medicine, University of Adelaide, Adelaide, Australia. 2The Robinson Research Institute, University of Adelaide, Adelaide, Australia. 3Discipline of Surgery, School of Medicine, The Queen Elizabeth Hospital, University of Adelaide, DX465702, 28 Woodville Rd, Woodville 5011, Australia. 4The University of Melbourne Department of Surgery, St Vincent’s Hospital Melbourne, Fitzroy, Australia. 5Metastasis Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia. 6The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia. 7Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Queensland University of Technology and Translational Research Institute, Queensland, Australia. 8School of Veterinary Sciences, University of Adelaide, Roseworthy, SA, Australia. 9MIRC and University of Edinburgh Centre for Reproductive Health, Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, UK.

Received: 14 April 2016 Accepted: 7 December 2016
Published online: 11 January 2017

References
1. Chua AC, Hodson LJ, Moldenhauer LM, Robertson SA, Ingman WV. Dual roles for macrophages in ovarian cycle-associated development and remodelling of the mammary gland epithelium. Development. 2010;137(24):4229–38.
2. Ingman WV, Wyckoff J, Gouven-Evans V, Condeelis J, Pollard JW. Macrophages promote collagen fibrillogenesis around terminal end buds of the developing mammary gland. Dev Dyn. 2006;235(12):3222–9.
3. Pollard JW, Heiniglmaisen F. Colony stimulating factor 1 is required for mammary gland development during pregnancy. Proc Natl Acad Sci U S A. 1994;91(2):9312–6.
4. Schwerkneger KL, Rosen JM, Cohen DA. Mammary gland macrophages: pleiotropic functions in mammary development. J Mammary Gland Biol Neoplasia. 2006;11(3–4):229–38.
5. O’Brien J, Martinson H, Durand-Roughley C, Schedin P. Macrophages are crucial for epithelial cell death and adipocyte repopulation during mammary gland involution. Development. 2012;139(2):269–75.
6. Gouven-Evans V, Rothenberg ME, Pollard JW. Postnatal mammary gland development requires macrophages and eosiophysins. Development. 2000;127(11):2269–82.
7. Hodson LJ, Chua AC, Evdokiiou A, Robertson SA, Ingman WV. Macrophage phenotype in the mammary gland fluctuates over the course of the estrous cycle and is regulated by ovarian steroid hormones. Biol Reprod. 2013;89(3):65.
8. Sun X, Ingman WV. Cytokine networks that mediate epithelial cell-macrophage crosstalk in the mammary gland: implications for development and cancer. J Mammary Gland Biol Neoplasia. 2014;19(2):191–201.
9. Yang J, Hawkins OE, Barham W, Gilchuk P, Boothby M, Ayers GD, Joyce S, Karin M, Yull FE, Richmond A. Myeloid iKbalpha promotes antitumor immunity by modulating CCL11 and the innate immune response. Cancer Res. 2014;74(24):7274–84.
10. Diefenbach A, Jameson AM, Liu SD, Shastri N, Raulet DH. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol. 2000;1(2):119–26.
11. Danoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 2004;1(1):11–22.
12. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23(11):549–55.
13. Qan BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39–51.
14. Gvionnikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–99.
15. Yadav A, Saini V, Arora S. MCP-1: chemoattractant with a role beyond immunity: a review. Clin Chim Acta. 2010;411(21-22):1570–9.
16. Deshmule SL, Kremslie S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interf Cytokine Res. 2009;29(6):313–26.
17. Soria G, Ber-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett. 2008;267(2):271–85.
18. Ueno T, Toi M, Saiy H, Musha M, Bando H, kurki K, Koike M, Inadera H, Matsusaka K. Significance of macrophage chemokinin receptor-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res. 2006;12(8):3282–9.
19. Qan BZ, Li J, Zhang H, Kitanura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475(7355):222–5.
20. Fujimoto H, Sangai T, Higii G, Ikehara A, Nagashima T, Miyazaki M, Ochiai A. Stromal MCP1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression. Int J Cancer. 2009;125(6):1276–84.
21. Arendt LM, McCreary J, Keller PJ, Baker DD, Naber SP, Seевaldt V, Kuperwasser C. Obesity promotes breast cancer by CCL2-mediated macrophage recruitment and angiogenesis. Cancer Res. 2013;73(19):5080–93.
22. Lu X, Kang Y. Chemokine (C-C motif) ligand 2 engages CCR2+ stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone. J Biol Chem. 2009;284(42):29087–96.
23. Lin SJ, Cawson J, Hill P, Haviv I, Jenkins M, Hopper JL, Southey MC, Campbell IG, Thompson EW. Image-guided sampling reveals increased stroma and lower glandular complexity in mammographically dense breast tissue. Breast Cancer Res Treat. 2011;128(2):505–16.
24. Alowami S, Troup S, Al-Haddad S, Kirkpatrick I, Watson PH. Mammographic density is related to stroma and stromal proteoglycan expression. Breast Cancer Res. 2003;5(5):R9–15.
25. Huo CW, Chew G, Hill P, Huang D, Ingman W, Hodson L, Brown KA, Magen Ay, Allam AH, McGhee E, et al. High mammary density is associated with an increase in stromal collagen and immune cells within the mammary epithelium. Breast Cancer Res. 2015;17(7):79.
26. Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, Jorga RA, Hislop G, Chiarella A, Minkin S, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 2007;356(3):227–36.

27. Ingman WV, Roeker RL, Wiekert K, Robertson SA. Null mutation in transforming growth factor beta 1 disrupts ovarian function and causes oocyte incompetence and early embryo arrest. Endocrinology. 2006;147(2):835–45.

28. Rutledge BJ, Rayburn H, Rosenberg R, North RJ, Gladue RP, Corless CL, Rolls BJ. High level monocye chemotactant protein-1 expression in transgenic mice increases their susceptibility to intracellular pathogens. J Immunol (Baltimore, Md: 1950). 1993;151(10):4838–43.

29. Huang AL, Ostrowski MC, Berard D, Hager GL. Glucocorticoid regulation of the HA-MuLV p21 gene confers by sequences from mouse mammary tumor virus. Cell. 1991;72:245–55.

30. Ingman WV, Robertson SA. Mammary gland development in transforming growth factor beta1 null mutant mice: systemic and epithelial effects. Biol Reprod. 2008;79(4):711–7.

31. Fata JE, Chaudhary V, Khokha R. Cellular turnover in the mammary gland is regulated by enhancing integrin signaling. Cell. 2009;139(5):891–903.

32. Chua CLH, Robertson SA, Ingman WV. Dual roles of macrophages in ovarian cycle-associated development and remodelling of the mammary gland epithelium. Development. 2010;137(24):4229–38.

33. Jasper MJ, Tremellen KP, Robertson SA. Primary unexplained infertility is associated with reduced expression of the T-regulatory cell transcription factor FoxP3 in endometrial tissue. Mol Hum Reprod. 2006;12(5):301–8.

34. Rolls BJ, Morrison ED, Stiles CD. Cloning and expression of JE, a gene inducible by platelet-derived growth factor and whose product has cytokine-like properties. Proc Natl Acad Sci U S A. 1988;85(11):3738–42.

35. Kanda H, Tateya S, Kishimoto T, Kitazawa R, Kitazawa S, Miyachi H, Maeda S, Egashira K, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest. 2009;119(6):1494–505.

36. Fuentes ME, Durham SK, Svedler MR, Lewin AC, Megill JR, Bravo R, Ingman WV, Robertson SA. Null mutation in the Ha-MuLV p21 gene confers by sequences from mouse mammary tumor virus. Cell. 1991;72:245–55.

37. Lu B, Rutledge BJ, Gu L, Fiorillo J, Lukacs NW, Kunkel SL, North R, Gerard C, Rolls BJ. Abnormalities in monocyte recruitment and cytokine expression in mammary gland mammary tumor protein-1 deficient mice. J Exp Med. 1998;187(4):601–8.

38. Dasari P, Sharkey DJ, Noordin E, Glynn DJ, Hodson LJ, Chin PY, Evdokiou A, Robertson SA, Ingman WV. Hormonal regulation of the cytokine microenvironment in the mammary gland. J Reprod Immunol. 2014;105:65–76.

39. O’Brien J, Lyons T, Monks J, Lucia MS, Wilson RS, Hines L, Man Y, Borges V, Schedin P. Alternatively activated macrophages and collagen remodeling characterize the postpartum involuting mammary gland across species. Am J Pathol. 2010;176(3):1241–55.

40. Glynn DJ, Hutchinson MR, Ingman WV. Toll-like receptor 4 regulates lipopolysaccharide-induced inflammation and lactation insufficiency in a mouse model of mastitis. Biol Reprod. 2014;90(5):91.

41. Chua AC, Hodson LJ, Moldenhauer LM, Robertson SA, Ingman WV. Dual roles for macrophages in ovarian cycle-associated development and remodelling of the mammary gland epithelium. Development. 2010;137.

42. Maller O, Martinson H, Schedin P. Extracellular matrix composition reveals complex and dynamic stromal-epithelial interactions in the mammalian mammary gland. J Mammary Gland Biol Neoplasia. 2015;20(3):1267–75.

43. Baran CP, Opalek JM, Mckamen S, Newland CA, O’Brien Jr JM, Hunter MG, Bringardner BD, Monick MM, Bigstock DR, Stromberg EC, et al. Important roles for macrophage colony-stimulating factor, CC chemokine ligand 2, and mononuclear phagocytes in the pathogenesis of pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176(1):78–89.

44. Lloyd CM, Dorf ME, Proudfit A, Salant DJ, Gutierrez-Ramos JC. Role of MCP-1 and RANTES in inflammation and progression to fibrosis during murine crescentic nephritis. J Leukoc Biol. 1997;62(5):676–80.

45. Rollins BJ, Cullen P, Plenz G, Renbæk H, Rautenberg J. Human macrophages synthesize type V collagen in vitro and in the atherosclerotic plaque. FASEB J. 1999;13(11):1445–57.

46. Schoor M, Cullen P, Lorkowski J, Stolle K, Renbæk H, Troyer D, Rautenberg J, Lorkowski S. Production of type VI collagen by human macrophages: a new dimension in macrophage functional heterogeneity. J Immunol (Baltimore, Md: 1950). 2008;180(8):5707–19.

47. Schmid-Kottas A, Gross HJ, Menke A, Weidenbach H, Adler G, Seich M, Beger H, Grunert A, Bachem GM. Lipopolysaccharide-activated macrophages stimulate the synthesis of collagen type I and C-fibronectin in cultured pancreatic stellate cells. Am J Pathol. 1999;155(5):1749–58.

48. Wong L, Hutson PR, Bushman W. Prostatic inflammation induces fibrosis in a mouse model of chronic bacterial infection. PLoS One. 2014;9(6):e100770.

49. McCormack VA, dos Santos SI. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15(8):1159–69.

50. Boyd NF, Martin LJ, Stone J, Greenberg C, Minkin S, Yaffe MJ. Mammographic densities as a marker of human breast cancer risk and their use in chemoprevention. Curr Oncol Rep. 2001;3(4):314–21.

51. Ghilardi G, Boldini ML, La Torre A, Battaglioli L, Scora R. Breast cancer progression and host polymorphisms in the chemokine system: role of the macrophage chemotactant protein-1 (MCP-1) -2518 G allele. Clin Chem. 2005;51(4):452–5.

52. Rovin BH, Lu L, Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun. 1999;259(2):344–8.

53. Zaffropoulos A, Crikas N, Passam AM, Spandidos DA. Significant involvement of CCR2-64I and CXCL12-3a in the development of sporadic breast cancer. Breast Cancer Res Treat. 2012;131(1):267–75.

54. Provenzano PP, Inman DR, Eliceiri KW, Knittel JK, Van L, Rueden CT, White JG, Keely PJ. Collagen density promotes mammary tumor initiation and progression. BMC Med. 2008;6(11).

55. Ghosh K, Brandt KR, Reynolds C, Scott CG, Pankratz VS, Rehle DL, Lingle WL, Odogwu T, Radisky DC, Visscher DW, et al. Tissue composition of mammographically dense and non-dense breast tissue. Breast Cancer Res Treat. 2012;131(1):267–75.

56. Guo YP, Martin LJ, Hanna W, Banerjee D, Miller N, Fishel E, Khokha R, Boyd NF. Growth factors and stromal matrix proteins associated with mammographic densities. Cancer Epidemiol Biomarkers Prev. 2001;10(3):243–8.

57. Chew GL, Hui CW, Huang D, Hill P, Cawson J, Frazer H, Hopper JL, Haviv I, Henderson MA, Britt K, et al. Increased COX-2 expression in epithelial and stromal cells of high mammographic density tissues and in a xenograft model of mammographic density. Breast Cancer Res Treat. 2015;153(1):889–90.

58. McConnell JC, O’Connell OV, Brennan K, Weiping L, Howe M, Joseph L, Keely PJ. Macrophage functional heterogeneity. J Immunol (Baltimore, Md: 1950). 2005;175(10):4838–43.

59. Esbona K, Inman D, Saha S, Jeffery J, Schedin P, Wilke L, Keely P. COX-2 in Chronic Inflammation Driving Breast Cancer Growth and Metastasis. Breast Cancer Res. 2016;18(1):5.

60. Zhao YS, Zhu S, Li XY, Wang D, Hu F, Li DD, Zhang WC, Li X. Association between NSAI1’s use and breast cancer risk: a systematic review and meta-analysis. Breast Cancer Res Treat. 2009;117(1):141–50.

61. Bergman A, Saunders C, Ramsay RG, Thompson EW. New Insights on COX-2 in Chronic Inflammation Driving Breast Cancer Growth and Metastasis. J Mammary Gland Biol Neoplasia. 2015;20(3):410–19.

62. Esbona K, Inman D, Saha S, Jeffery J, Schedin P, Wilke L, Keely P. COX-2 modulates mammary tumor progression in response to collagen density. Breast Cancer Res. 2016;18(1):35.

63. Stone J, Willenberg L, Apicella C, Telaro S, Hopper J. The association between mammographic density measures and aspirin or other NSAID use. Breast Cancer Res Treat. 2012;132(1):259–66.

64. Terry MB, Buist DS, Trentham-Dietz A, James-Todd TM, Liao Y. Nonsteroidal anti-inflammatory drugs and change in mammographic density: a cohort study using Pharmacy records on over 20,000 postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2008;17(5):1088–95.